Breast Cancer Clinical Trial of Chemotherapy and Trastuzumab: Potential Tool to Identify Cardiac Modifying Variants of Dilated Cardiomyopathy

Doxorubicin and the ERBB2 targeted therapy, trastuzumab, are routinely used in the treatment of HER2+ breast cancer. In mouse models, doxorubicin is known to cause cardiomyopathy and conditional cardiac knock out of Erbb2 results in dilated cardiomyopathy and increased sensitivity to doxorubicin-ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Serie, Daniel J., Crook, Julia E., Necela, Brian M., Axenfeld, Bianca C., Dockter, Travis J., Colon-Otero, Gerardo, Perez, Edith A., Thompson, E. Aubrey, Norton, Nadine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715703/
https://www.ncbi.nlm.nih.gov/pubmed/29367538
http://dx.doi.org/10.3390/jcdd4020006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715703/
https://www.ncbi.nlm.nih.gov/pubmed/29367538
http://dx.doi.org/10.3390/jcdd4020006

Ejemplares similares